Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

Autor: Gangishetti, Umesh1 umesh.gangishetti@emory.edu, Christina Howell, J.1,2 jhowel4@emory.edu, Perrin, Richard J.3,4 rperrin@wustl.edu, Louneva, Natalia4 Natalia.louneva@uphs.upenn.edu, Watts, Kelly D.1 kdwatts@emory.edu, Kollhoff, Alexander1 akollho@emory.edu, Grossman, Murray5,6,7 mgrossma@pennmed.upenn.edu, Wolk, David A.7,8 david.wolk@uphs.upenn.edu, Shaw, Leslie M.9 les.shaw@uphs.upenn.edu, Morris, John C.3,10 morrisj@wustl.edu, Trojanowski, John Q.5,8,9 trojanow@mail.med.upenn.edu, Fagan, Anne M.3,10 fagana@neuro.wustl.edu, Arnold, Steven E.5,8,11 searnold@mgh.harvard.edu, Hu, William T.1,2 william.hu@emory.edu
Zdroj: Alzheimer's Research & Therapy. 9/25/2018, Vol. 10 Issue 1, pN.PAG-N.PAG. 1p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje